title: Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
abstract: Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM). Recently, there has been an increasing awareness of progressive and enhancing lesions on MR images immediately after treatment. These lesions may be a treatment effect, so-called pseudoprogression. We experienced one case pathologically and clinically diagnosed as pseudoprogression. The lesion showed a high apparent diffusion coefficient on diffusion-weighted imaging, low blood volume on perfusion imaging, and low uptake of 18F-fluorodeoxyglucose on positron emission tomography. The lesion was pathologically diagnosed as pseudoprogression after additional surgical resection.
authors.affiliation: Departments of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Shirakawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshiura
authors.forename: Akio
authors.initials: A
authors.lastname: Hiwatashi
authors.forename: Koji
authors.initials: K
authors.lastname: Yamashita
authors.forename: Hironori
authors.initials: H
authors.lastname: Kamano
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Shioyama
authors.forename: Kouichiro
authors.initials: K
authors.lastname: Abe
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Amano
authors.forename: Akira
authors.initials: A
authors.lastname: Nakamizo
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshimoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Honda
authors.forename: Rina
authors.initials: R
authors.lastname: Torisu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Suzuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Honda
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D005909:Glioblastoma / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D049268:Positron-Emission Tomography; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide